^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Gastrointestinal Stromal Tumor
    Drug:imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    10/30/2020
    Excerpt:
    Gastrointestinal Stromal Tumors: First-line therapy…Preferred Regimens…Imatinib (category 1)...
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Gastrointestinal Stromal Tumors: Systemic Therapy agents and regimens for unresectable GIST with significant morbidity...Useful in certain circumstances…Everolimus + TKI…TKIs to be considered for use in combination with everolimus include imatinib, sunitinib, or regorafenib
    Secondary therapy:
    everolimus
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Ann Oncol
    Title:

    Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Spanish Group for Research on Sarcomas (GEIS)

    Published date:
    01/19/2021
    Excerpt:
    With 9.1 years of follow-up, a trend toward better long-term IFFS in imatinib-treated patients was observed in the high-risk subgroup...the results reported by the Scandinavian/German trial, showing a sustained small but significant long-term OS benefit in high risk GIST patients treated with 3 years of adjuvant imatinib.
    DOI:
    10.1016/j.annonc.2021.01.004
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    JAMA Oncol
    Title:

    Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up

    Published date:
    08/01/2020
    Excerpt:
    To evaluate the effect of adjuvant imatinib on OS of patients who have a high estimated risk for GIST recurrence after macroscopically complete surgery....In the 36-month group, 5-year OS and 10-year OS rates were 92.0% and 79.0%, respectively, and in the 12-month group 85.5% and 65.3% (HR, 0.55; 95% CI, 0.37-0.83; P = .004)....Three years of adjuvant imatinib is superior in efficacy compared with 1 year of imatinib.
    DOI:
    10.1001/jamaoncol.2020.2091